Abstract
Modulation of sex steroid action on the growth plate can, at least theoretically, increase adult height in children and adolescents with idiopathic short stature. Gonadotropin-releasing hormone (GnRH) analog therapy during adolescence has been shown effective in a placebo-controlled study, but to obtain clinically significant increases in adult height, the treatment duration must be lengthy (several years). Furthermore, such treatment seems to compromise bone health and, because of the resulting delay in pubertal development, likely has psychosocial consequences. Therefore, GnRH analogs are no longer recommended to augment height in adolescents with short stature and normally timed puberty. Aromatase inhibitors are probably more effective than GnRH analogs in promoting increased adult height in children with short stature and, unlike GnRH analogs, do not delay pubertal development in males. However, due to a dearth of safety data with aromatase inhibitors for the treatment of short stature, their use outside a research setting is currently not recommended. Positive effects of anabolic steroids on adult height have not been documented
Journal Section:
Paper
References
1.
Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–1061 [Erratum, N Engl J Med 1995;332:131].
[PubMed]
2.
Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689–3698.
[PubMed]
3.
Weise M, De-Levi S, Barnes KM, Gafni RI, Abad V, Baron J: Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci USA 2001;98:6871–6876.
[PubMed]
4.
Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr: Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711–4716.
[PubMed]
5.
Brauner R, Adan L, Malandry F, Zantleifer D: Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 1994;79:415–420.
[PubMed]
6.
Paul D, Conte FA, Grumbach MM, Kaplan SL: Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995;80:546–551.
[PubMed]
7.
Vizmanos B, Martí-Henneberg C, Clivillé R, Moreno A, Fernandez-Ballart J: Age of pubertal onset affects the intensity and duration of pubertal growth peak but not final height. Am J Human Biol 2001;13:409–416.
[PubMed]
8.
Carel JC, Hay F, Coutant R, Rodrigue D, Chaussain JL: Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J Clin Endocrinol Metab 1996;81:3318–3322.
[PubMed]
9.
Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, Bougnères PF: Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab 1999;84:3575–3578.
[PubMed]
10.
Lanes R, Gunczler P: Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol (Oxf) 1998;49:197–202.
[PubMed]
11.
Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr: Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908–917.
[PubMed]
12.
Mericq MV, Eggers M, Avila A, Cutler GB Jr, Cassorla F: Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000;85:569–573.
[PubMed]
13.
Pasquino AM, Pucarelli I, Roggini M, Segni M: Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab 2000;85:619–622.
[PubMed]
14.
Mul D, Wit JM, Oostdijk W, Van den Broeck J, Dutch Advisory Group on Growth Hormone: The effect of pubertal delay by GnRH agonist in GH-deficient children on final height. J Clin Endocrinol Metab 2001;86:4655–4656.
[PubMed]
15.
van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJ, Jansen M, Verhoeven-Wind L, Delemarre-van de Waal HA, de Muinck Keizer-Schrama SM, Leusink G, Roos JC, Wit JMJ: Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. Clin Endocrinol Metab 2007;92:1402–1408.
16.
Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr: Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999;84:175–178.
[PubMed]
17.
Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr: Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85:1114–1120.
[PubMed]
18.
Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743–1748.
[PubMed]
19.
Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396–6402.
[PubMed]
20.
Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006;64:510–513.
[PubMed]
21.
Dunkel L: Update on the role of aromatase inhibitors in growth disorders. Horm Res 2009;71:57–63.
[PubMed]
22.
Schroor EJ, van Weissenbruch MM, Knibbe P, Delemarre-van de Waal HA: The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty. Eur J Pediatr 1995;154:953–957.
[PubMed]
23.
Tse WY, Buyukgebiz A, Hindmarsh PC, Stanhope R, Preece MA, Brook CGD: Long-term outcome of oxandrolone treatment in boys with constitutional delay of growth and puberty. J Pediatr 1990;117:588–591.
[PubMed]
24.
Wickman S, Dunkel L: Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001;86:4887–4894.
[PubMed]
25.
Lampit M, Hochberg Z: Androgen therapy in constitutional delay of growth. Horm Res 2003;59:270–275.
[PubMed]
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
